The CSL Limited (ASX: CSL) share price has climbed 3% in the past month, but could it go higher?
CSL shares fell 0.37% today to $295.64. In comparison, the S&P/ASX 200 Index (ASX: XJO) leapt 0.07% on Monday.
So what is the outlook for the CSL share price?
CSL is a global biotech giant working on vaccines and plasma products to treat diseases.
Recently, Wilson Asset Management experts have recommended shareholders buy CSL shares, as my Foolish colleague Tony reported.
Analyst Anna Milne highlighted the company’s Behring business has been “under earning for a number of years” and is “really starting to hit it’s strap”.
Further, Milne pushed the company’s plasma and vaccine advantages and how that would help the company. Commenting on CSL’s Seqirus influenza business, she said:
Seqiris is the vaccine business… it’s been a pretty horrendous flu season Down Under and we think that’ll probably translate to the same in the northern hemisphere.
In addition, Milne commented on the company’s Vifor Pharma acquisition:
The Vifor transaction, which has been delayed, but management is still very confident that it’s going to close and we’re really excited about the pipeline of drugs there.
So CSL’s a buy.
On 2 August, CSL revealed to the market it has received all the regulatory clearance required to finalise the acquisition of Vifor Pharma.
Completion of this acquisition is due tomorrow, on 9 August.
CSL is due to report earnings in FY22 on Wednesday next week.
The CSL share price has slipped 0.78% in the past year, while it has gained climbed 1.7% year to date. For perspective, the ASX 200 has shed nearly 7% in a year.
CSL has a market capitalisation of more than $142 billion based on the current share price.
Source: Read More